ליינקס ישראל - עברית - Ministry of Health

ליינקס

teva israel ltd - xylometazoline hydrochloride - ספריי לאף - xylometazoline hydrochloride 1 mg/ml - xylometazoline

סרדלגה ישראל - עברית - Ministry of Health

סרדלגה

sanofi israel ltd - eliglustat - קפסולה קשיחה - eliglustat 84.4 mg - eliglustat

סביעור ישראל - עברית - Ministry of Health

סביעור

teva israel ltd - cetrimide; chlorhexidine hydrochloride - קרם - cetrimide 0.5 %w/w; chlorhexidine hydrochloride 0.1 %w/w - chlorhexidine, combinations - chlorhexidine, combinations - first aid antiseptic for external use in treatment for minor injuries, wounds and burns.

פוסרנול 500 מג טבליות לעיסה ישראל - עברית - Ministry of Health

פוסרנול 500 מג טבליות לעיסה

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 500 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

פוסרנול     750 מג טבליות לעיסה ישראל - עברית - Ministry of Health

פוסרנול 750 מג טבליות לעיסה

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

פוסרנול  1000 מג בליות לעיסה ישראל - עברית - Ministry of Health

פוסרנול 1000 מג בליות לעיסה

takeda israel ltd - lanthanum as carbonate hydrate - טבליות לעיסות - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate - lanthanum carbonate - fosrenol is indicated as a phosphate binding agent for use in the control of hyperphosphatemia in crf patients on haemodyalisis or continuous ambulatory peritoneal dialysis (capd).fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels > or = 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

פוסרנול 1000 מג אבקה למתן דרך הפה ישראל - עברית - Ministry of Health

פוסרנול 1000 מג אבקה למתן דרך הפה

takeda israel ltd - lanthanum as carbonate hydrate - אבקה - lanthanum as carbonate hydrate 1000 mg - lanthanum carbonate

פוסרנול 750 מג אבקה למתן דרך הפה ישראל - עברית - Ministry of Health

פוסרנול 750 מג אבקה למתן דרך הפה

takeda israel ltd - lanthanum as carbonate hydrate - אבקה - lanthanum as carbonate hydrate 750 mg - lanthanum carbonate

אביאנה ישראל - עברית - Ministry of Health

אביאנה

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - טבליות מצופות פילם - estradiol as hemihydrate 0.5 mg; norethisterone acetate 0.1 mg - estradiol, combinations - estradiol, combinations - eviana is indicated for women who have a uterus for the: treatment of moderate to severe vasomotor symptoms associated with menopause. prevention of postmenopausal osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

לנסופרזול טבע  30 מג ישראל - עברית - Ministry of Health

לנסופרזול טבע 30 מג

teva israel ltd - lansoprazole - קפסולות - lansoprazole 30 mg - lansoprazole - lansoprazole - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.